AHA/ACC GUIDELINE
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
Endorsed by the National Heart, Lung, and Blood Institute
Sidney C. Smith, Jr, MD,
Jerilyn Allen, RN, ScD,
Steven N. Blair, PED,
Robert O. Bonow, MD,
Lawrence M. Brass, MD ,
Gregg C. Fonarow, MD,
Scott M. Grundy, MD, PhD,
Loren Hiratzka, MD,
Daniel Jones, MD,
Harlan M. Krumholz, MD,
Lori Mosca, MD, PhD, MPH,
Richard C. Pasternak, MD*,
Thomas Pearson, MD, MPH, PhD,
Marc A. Pfeffer, MD, PhD and
Kathryn A. Taubert, PhD
Key Words: AHA Scientific Statements • coronary disease • vascular diseases • risk factors • prevention
Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC) consensus statement on secondary prevention (1), important evidence from clinical trials has emerged that further supports and broadens the merits of aggressive risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. This growing body of evidence confirms that aggressive comprehensive risk factor management improves survival, reduces recurrent events and the need for interventional procedures, and improves quality of life for these patients.
Compelling evidence from recent clinical trials and revised practice guidelines provided the impetus for this update of the 2001 recommendations with evidence-based results (Table 1). Classification of Recommendations and Level of Evidence are expressed in ACC/AHA format, as detailed in Tables 2 and 3. Recommendations made herein are based largely on major practice guidelines from the National Institutes of Health and ACC/AHA. In many cases, these practice guidelines were supplemented by research findings published after the publication of the primary reference(s). Thus, the development of the present statement involved a process of partial adaptation of other guideline statements and reports and supplemental literature searches 2–32). (For specific search criteria, see the Appendix.) The findings from additional lipid reduction trials (33–37) involving more than 50 000 patients resulted in new optional therapeutic targets, which were outlined in the 2004 update of the National Heart, Lung, and Blood Institute’s Adult Treatment Panel (ATP) III report (6). These changes defined optional lower target cholesterol levels for very high-risk coronary heart disease (CHD) patients, especially those with acute coronary syndromes, and expanded indications for drug treatment. Subsequent to the 2004 update of ATP III, 2 additional trials (8,9) demonstrated cardiovascular benefit for lipid lowering significantly below current cholesterol goal levels for those with chronic CHD. These new trials allow for alterations in guidelines, such that low-density lipoprotein cholesterol (LDL-C) should be <100 mg/dL for all patients with CHD and other clinical forms of atherosclerotic disease, but in addition, it is reasonable to treat to LDL-C <70 mg/dL in such patients. When the <70-mg/dL target is chosen, it may be prudent to increase statin therapy in a graded fashion to determine a patient’s response and tolerance. Furthermore, if it is not possible to attain LDL-C <70 mg/dL because of a high baseline LDL-C, it generally is possible to achieve LDL-C reductions of >50% with either statins or LDL-C–lowering drug combinations. Moreover, this guideline for patients with atherosclerotic disease does not modify the recommendations of the 2004 ATP III update for patients without atherosclerotic disease who have diabetes or multiple risk factors and a 10-year risk level for CHD >20%. In the latter 2 types of high-risk patients, the recommended LDL-C goal of <100 mg/dL has not changed. Finally, to avoid any misunderstanding about cholesterol management in general, it must be emphasized that a reasonable cholesterol level of <70 mg/dL does not apply to other types of lower-risk individuals who do not have CHD or other forms of atherosclerotic disease; in such cases, recommendations contained in the 2004 ATP III update still pertain.
Trials involving other secondary prevention therapies also have influenced major practice guidelines used to formulate the recommendations in this update. Thus, specific recommendations for clopidogrel use in post–acute coronary syndrome or post–percutaneous coronary intervention–stented patients are now included in this 2006 update. The present update also recommends lower-dose aspirin for chronic therapy. The results of additional studies have further confirmed the benefit of aldosterone antagonist therapy among patients with impaired left ventricular function. Finally, recently published findings of a trial involving angiotensin-converting enzyme inhibitor therapy among patients at relatively low risk with stable coronary disease and normal left ventricular function influenced the recommendations (26).
The writing group has for the first time added a recommendation with regard to influenza vaccination. According to the US Centers for Disease Control and Prevention, vaccination with inactivated influenza vaccine is recommended for individuals who have chronic disorders of the cardiovascular system because they are at increased risk for complications from influenza (38).
The writing group emphasizes the importance of giving consideration to the use of cardiovascular medications that have been proved in randomized clinical trials to be of benefit. This strengthens the evidence-based foundation for therapeutic application of these guidelines. The committee acknowledges that ethnic minorities, women, and the elderly are underrepresented in many trials and urges physician and patient participation in trials that will provide additional evidence with regard to therapeutic strategies for these groups of patients.
In the 11 years since the guidelines were first published, 2 other developments have made them even more important in clinical care. First, the aging of the population continues to expand the number of patients living with a diagnosis of cardiovascular disease (now estimated at 13 million for coronary heart disease alone) who might benefit from these therapies. Second, multiple studies of the use of these recommended therapies in appropriate patients, although showing slow improvement, continue to support the discouraging conclusion that many patients in whom therapies are indicated are not receiving them in actual clinical practice. The AHA and ACC recommend the use of programs such as the AHA’s Get With The Guidelines (39) or the ACC’s Guidelines Applied to Practice (40) to identify appropriate patients for therapy, provide practitioners with useful reminders based on the guidelines, and continuously assess the success achieved in providing these therapies to the patients who can benefit from them.
 |
Appendix
|
|---|
|
Disclosures
|
|---|
|
Footnotes
|
|---|
This document was approved by the American Heart Association Science Advisory and Coordinating Committee on November 11, 2005, and by the American College of Cardiology Foundation Board of Trustees on November 10, 2005.
The American Heart Association and American College of Cardiology make every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. The relationships with industry for writing committee members, as well as peer reviewers of the document, are located before the references.
When this document is cited, the American College of Cardiology requests that the following citation format be used: Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol 2006;47:2130–9. doi:10.1016/j.jacc.2006.04.026.
This article has been copublished in the May 16, 2006, issue of the Circulation (Circulation 2006;113).
Copies: This document is available on the World Wide Web sites of the American Heart Association (www.americanheart.org) and the American College of Cardiology (www.acc.org). A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0361. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4121, fax 410-528-4264, or e-mail mailto:kramsay{at}lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.
* Dr Pasternak withdrew from the Writing Group on June 22, 2004, when he accepted an offer of employment as Vice President, Clinical Research, Cardiovascular and Atherosclerosis, at Merck Research Laboratories. The remaining members of the Writing Group were advised of his change in status before this Scientific Statement was finalized, and they affirmed their support of the Statement with subsequent revisions after his departure. 
 Deceased.
|
References
|
|---|
1. Smith Jr SC, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology Circulation 2001;104:1577-1579.[Free Full Text]2. Mosca L, Appel LJ, Benjamin EJ, et al. American Heart Association Evidence-based guidelines for cardiovascular disease prevention in women Circulation 2004;109:672-693.[Free Full Text] 3. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Washington, DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; May 27, 2004. Available at: http://www.surgeongeneral.gov/library/smokingconsequences. Accessed March 15, 2006.. 4. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureNational Heart, Lung, and Blood InstituteNational High Blood Pressure Education Program Coordinating Committee Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 2003;42:1206-1252.[Abstract/Free Full Text] 5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001;285:2486-2497.[Free Full Text] 6. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood InstituteAmerican College of Cardiology FoundationAmerican Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 2004;110:227-239Erratum in: Circulation 2004;110:763.[Abstract/Free Full Text] 7. Kris-Etherton PM, Harris WS, Appel LJ, American Heart AssociationNutrition Committee Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 2002;106:2747-2757Erratum in: Circulation 2003;107:512.[Free Full Text] 8. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 2005;352:1425-1435.[Abstract/Free Full Text] 9. Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 2005;294:2437-2445Erratum in: JAMA 2005;294:3092.[Abstract/Free Full Text] 10. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatmentprospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278Erratum in: Lancet 2005;366:1358.[CrossRef][Web of Science][Medline] 11. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemiathe Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-473Erratum in: Am Heart J 2005;149:882.[CrossRef][Web of Science][Medline] 12. de Lemos JA, Blazing MA, Wiviott SD, et al. A to Z Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromesphase Z of the A to Z trial. JAMA 2004;292:1307-1316.[Abstract/Free Full Text] 13. Thompson PD, Buchner D, Pina IL, et al. American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Rehabilitation, and PreventionAmerican Heart Association Council on Nutrition, Physical Activity, and Metabolism Subcommittee on Physical Activity Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular diseasea statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107:3109-3116.[Free Full Text] 14. UK Department of Health. At Least Five a Week: Evidence on the Impact of Physical Activity and Its Relationship to Health: A Report From the Chief Medical Officer. London, England: Wellington House; April 29, 2004. Available at: http://www.dh.gov.uk/assetRoot/04/08/09/81/04080981.pdf. Accessed March 15, 2006.. 15. Pate RR, Pratt M, Blair SN, et al. Physical activity and public healtha recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273:402-407.[Abstract/Free Full Text] 16. U.S. Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996. Available at: http://www.cdc.gov/nccdphp/sgr/summary.htm. Accessed March 15, 2006.. 17. National Institutes of Health; National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health; National Heart, Lung, and Blood Institute; September 1998. Publication No. 98-4083. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf. Accessed March 15, 2006.. 18. Klein S, Burke LE, Bray GA, et al. American Heart Association Council on Nutrition, Physical Activity, and Metabolism Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation Circulation 2004;110:2952-2967.[Abstract/Free Full Text] 19. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndromean American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752Errata in: Circulation 2005;112:e297; Circulation 2005;112:e298.[Free Full Text] 20. American Diabetes Association Standards of medical care in diabetes Diabetes Care 2004;27(Suppl 1):S15-S35. 21. Antman EM, Anbe DT, Armstrong PW, et al. American College of CardiologyAmerican Heart Association Task Force on Practice GuidelinesCanadian Cardiovascular Society ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarctiona report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:e82-e292Erratum in: Circulation 2005;111:2013–4.[Free Full Text] 22. Gibbons RJ, Abrams J, Chatterjee K, et al. American College of CardiologyAmerican Heart Association Task Force on Practice GuidelinesCommittee on the Management of Patients With Chronic Stable Angina ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary articlea report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003;107:149-158.[Free Full Text] 23. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary interventiona report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166-e286Available at: http://circ.ahajournals.org/cgi/reprint/113/7/e166. Accessed March 15, 2006.[Free Full Text] 24. Eagle KA, Guyton RA, Davidoff R, et al. American College of Cardiology; American Heart Association ACC/AHA 2004 guideline update for coronary artery bypass graft surgerya report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110:e340-e437Erratum in: Circulation 2005;111:2014.[Free Full Text] 25. Ferraris VA, Ferraris SP, Moliterno DJ, et al. Society of Thoracic Surgeons The Society of Thoracic Surgeons practice guideline seriesaspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg 2005;79:1454-1461.[Free Full Text] 26. Braunwald E, Domanski MJ, Fowler SE, et al. PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 2004;351:2058-2068.[Abstract/Free Full Text] 27. Braunwald E, Antman EM, Beasley JW, et al. American College of CardiologyAmerican Heart AssociationCommittee on the Management of Patients With Unstable Angina ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary articlea report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-1374.[Free Full Text] 28. Hunt SA, Abraham WT, Chin MH, et al. American College of CardiologyAmerican Heart Association Task Force on Practice GuidelinesAmerican College of Chest PhysiciansInternational Society for Heart and Lung TransplantationHeart Rhythm Society ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society Circulation 2005;112:e154-e235.[Free Full Text] 29. Coull BM, Williams LS, Goldstein LB, et al. Joint Stroke Guideline Development Committee of the American Academy of NeurologyAmerican Stroke Association Anticoagulants and antiplatelet agents in acute ischemic strokereport of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 2002;33:1934-1942.[Free Full Text] 30. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 2003;349:1893-1906Erratum in: N Engl J Med 2004;350:203.[Abstract/Free Full Text] 31. McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitorsthe CHARM-Added trial. Lancet 2003;362:767-771.[CrossRef][Web of Science][Medline] 32. Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitorsthe CHARM-Alternative trial. Lancet 2003;362:772-776.[CrossRef][Web of Science][Medline] 33. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 2004;350:1495-1504Erratum in: N Engl J Med 2006;354:778.[Abstract/Free Full Text] 34. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individualsa randomised placebo-controlled trial. Lancet 2002;360:7-22Summary for patients in: Curr Cardiol Rep 2002;4:486–7.[CrossRef][Web of Science][Medline] 35. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER Study Group PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 2002;360:1623-1630.[CrossRef][Web of Science][Medline] 36. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 2002;288:2998-3007.[Abstract/Free Full Text] 37. Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA)a multicentre randomised controlled trial. Lancet 2003;361:1149-1158.[CrossRef][Web of Science][Medline] 38. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB, Advisory Committee on Immunization Practices (ACIP)Centers for Disease Control and Prevention (CDC) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 2005;54(RR-8):1-40Erratum in: MMWR Morb Mortal Wkly Rep 2005;54(30):750.[Medline] 39. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary preventionpilot results. Arch Intern Med 2004;164:203-209.[Abstract/Free Full Text] 40. Mehta RH, Montoye CK, Gallogly M, et al. GAP Steering Committee of the American College of Cardiology Improving quality of care for acute myocardial infarctionThe Guidelines Applied in Practice (GAP) Initiative. JAMA 2002;287:1269-1276.[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
L. B. Daniels and E. Barrett-Connor
Can natriuretic peptides help identify heart failure patients for whom statins are beneficial?
J. Am. Coll. Cardiol.,
November 10, 2009;
54(20):
1860 - 1861.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Peterson, J. A. Spertus, D. J. Cohen, M. A. Hlatky, A. S. Go, B. G. Vickrey, J. L. Saver, and P. C. Hinton
Vision and Creation of the American Heart Association Pharmaceutical Roundtable Outcomes Research Centers
Circ Cardiovasc Qual Outcomes,
November 1, 2009;
2(6):
663 - 670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American College of Cardiology Foundation, American Heart Association, American College of Physicians Task Force on Compe, American Academy of Neurology, American Association of Cardiovascular and Pulmona, American College of Preventive Medicine, American Diabetes Association, American Society of Hypertension, Association of Black Cardiologists, National Lipid Association, et al.
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease.
J. Am. Coll. Cardiol.,
September 29, 2009;
54(14):
1336 - 1363.
[Full Text]
[PDF]
|
|
|
|
|
|
|
WRITING COMMITTEE MEMBERS, C. N. Bairey Merz, M. J. Alberts, G. J. Balady, C. M. Ballantyne, K. Berra, H. R. Black, R. S. Blumenthal, M. H. Davidson, S. B. Fazio, et al.
ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association
Circulation,
September 29, 2009;
120(13):
e100 - e126.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Levitt, M. J. Clark, P. M. Jenkins, J. R. Martens, and J. R. Traynor
Differential Effect of Membrane Cholesterol Removal on {micro}- and {delta}-Opioid Receptors: A PARALLEL COMPARISON OF ACUTE AND CHRONIC SIGNALING TO ADENYLYL CYCLASE
J. Biol. Chem.,
August 14, 2009;
284(33):
22108 - 22122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. O'Keefe, M. D. Carter, and C. J. Lavie
Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach
Mayo Clin. Proc.,
August 1, 2009;
84(8):
741 - 757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Jackevicius, J. L. Cox, D. Carreon, J. V. Tu, S. Rinfret, D. So, H. Johansen, D. Kalavrouziotis, V. Demers, K. Humphries, et al.
Long-term trends in use of and expenditures for cardiovascular medications in Canada
Can. Med. Assoc. J.,
July 7, 2009;
181(1-2):
E19 - E28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Varenhorst, S. James, D. Erlinge, J. T. Brandt, O. O. Braun, M. Man, A. Siegbahn, J. Walker, L. Wallentin, K. J. Winters, et al.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Eur. Heart J.,
July 2, 2009;
30(14):
1744 - 1752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Suaya, W. B. Stason, P. A. Ades, S.-L. T. Normand, and D. S. Shepard
Cardiac rehabilitation and survival in older coronary patients.
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1):
25 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Mensah
Fantastic voyage through cardiology: from 1969 to 2008.
J. Am. Coll. Cardiol.,
June 9, 2009;
53(23):
2197 - 2197.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Williams and K. W. Davidson
Psychological stress and cardiovascular disease with emphasis on acute coronary syndromes.
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
1339 - 1339.
[Full Text]
[PDF]
|
|
|
|
|
|
|
CORONARY REVASCULARIZATION WRITING GROUP, M. R. Patel, G. J. Dehmer, J. W. Hirshfeld, P. K. Smith, and J. A. Spertus
ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography
Circulation,
March 10, 2009;
119(9):
1330 - 1352.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hopkins and M. Limacher
The Role of Aspirin in Cardiovascular Disease Prevention in Women
American Journal of Lifestyle Medicine,
March 1, 2009;
3(2):
123 - 134.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. W. Casscells, E. Granger, A. M. Kress, A. Linton, M. Madjid, and L. Cottrell
Use of Oseltamivir After Influenza Infection Is Associated With Reduced Incidence of Recurrent Adverse Cardiovascular Outcomes Among Military Health System Beneficiaries With Prior Cardiovascular Diseases
Circ Cardiovasc Qual Outcomes,
March 1, 2009;
2(2):
108 - 115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Patel, G. J. Dehmer, J. W. Hirshfeld, P. K. Smith, and J. A. Spertus
ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography
J. Am. Coll. Cardiol.,
February 10, 2009;
53(6):
530 - 553.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Goumas
Is There Evidence-based Hypolipidemic Treatment With Clinical Benefit Beyond Statins?
Angiology,
February 1, 2009;
60(1):
93 - 98.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. Pallares, E. R Powers, P. L Zwerner, A. Fowler, R. Reeves, and J. M Nappi
Barriers to Clopidogrel Adherence Following Placement of Drug-Eluting Stents
Ann. Pharmacother.,
February 1, 2009;
43(2):
259 - 267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Adams Jr
Secondary Prevention of Atherothrombotic Events After Ischemic Stroke
Mayo Clin. Proc.,
January 1, 2009;
84(1):
43 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Reeves, T. Y. Wang, K. J. Reid, K. P. Alexander, C. Decker, H. Ahmad, J. A. Spertus, and E. D. Peterson
Dissociation Between Hospital Performance of the Smoking Cessation Counseling Quality Metric and Cessation Outcomes After Myocardial Infarction
Arch Intern Med,
October 27, 2008;
168(19):
2111 - 2117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Dawood, V. Vaccarino, K. J. Reid, J. A. Spertus, N. Hamid, S. Parashar, and for the PREMIER Registry Investigators
Predictors of Smoking Cessation After a Myocardial Infarction: The Role of Institutional Smoking Cessation Programs in Improving Success
Arch Intern Med,
October 13, 2008;
168(18):
1961 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Giraldez, R. P. Giugliano, S. Mohanavelu, S. A. Murphy, C. H. McCabe, C. P. Cannon, and E. Braunwald
Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis
J. Am. Coll. Cardiol.,
September 9, 2008;
52(11):
914 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Ballantyne, J. S. Raichlen, and V. A. Cain
Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Targets in High-Risk Patients: The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) Trial
J. Am. Coll. Cardiol.,
August 19, 2008;
52(8):
626 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Cohn and D. A. Duprez
Time to Foster a Rational Approach to Preventing Cardiovascular Morbid Events
J. Am. Coll. Cardiol.,
July 29, 2008;
52(5):
327 - 329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. DAVIDSON
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications
Cleveland Clinic Journal of Medicine,
July 1, 2008;
75(7):
479 - 496.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ciszewski, Z. T. Bilinska, L. B. Brydak, C. Kepka, M. Kruk, M. Romanowska, E. Ksiezycka, J. Przyluski, W. Piotrowski, R. Maczynska, et al.
Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study
Eur. Heart J.,
June 1, 2008;
29(11):
1350 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Wenger
Current Status of Cardiac Rehabilitation
J. Am. Coll. Cardiol.,
April 29, 2008;
51(17):
1619 - 1631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Guyton, B. G. Brown, S. Fazio, A. Polis, J. E. Tomassini, and A. M. Tershakovec
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
J. Am. Coll. Cardiol.,
April 22, 2008;
51(16):
1564 - 1572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Daugherty, P. M. Ho, J. A. Spertus, P. G. Jones, R. G. Bach, H. M. Krumholz, E. D. Peterson, J. S. Rumsfeld, and F. A. Masoudi
Association of Early Follow-up After Acute Myocardial Infarction With Higher Rates of Medication Use
Arch Intern Med,
March 10, 2008;
168(5):
485 - 491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Blumenthal, C. N. Bairey Merz, V. Bittner, and T. J. Gluckman
Task Force 10: Training in Preventive Cardiovascular Medicine
J. Am. Coll. Cardiol.,
January 22, 2008;
51(3):
393 - 398.
[Full Text]
[PDF]
|
|
|
|
|
|
|
American College of Cardiology/American Heart Asso, Developed in Collaboration With the Canadian Cardi, Endorsed by the American Academy of Family Physici, 2007 Writing Group to Review New Evidence and Upda, E. M. Antman, M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, et al.
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
210 - 247.
[Full Text]
[PDF]
|
|
|
|
|
|
|
American College of Cardiology/American Heart Asso, 2007 Writing Group to Review New Evidence and Upda, S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, and D. O. Williams
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
172 - 209.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Antman, M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, J. S. Hochman, H. M. Krumholz, G. A. Lamas, C. J. Mullany, et al.
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee
Circulation,
January 15, 2008;
117(2):
296 - 329.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, D. O. Williams, 2005 WRITING COMMITTEE MEMBERS, S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, et al.
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
Circulation,
January 15, 2008;
117(2):
261 - 295.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Brugts, E. Boersma, M. Chonchol, J. W. Deckers, M. Bertrand, W. J. Remme, R. Ferrari, K. Fox, M. L. Simoons, and on behalf of the EUROPA Investigators
The Cardioprotective Effects of the Angiotensin-Converting Enzyme Inhibitor Perindopril in Patients With Stable Coronary Artery Disease Are Not Modified by Mild to Moderate Renal Insufficiency: Insights From the EUROPA Trial
J. Am. Coll. Cardiol.,
November 27, 2007;
50(22):
2148 - 2155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Suaya, D. S. Shepard, S.-L. T. Normand, P. A. Ades, J. Prottas, and W. B. Stason
Use of Cardiac Rehabilitation by Medicare Beneficiaries After Myocardial Infarction or Coronary Bypass Surgery
Circulation,
October 9, 2007;
116(15):
1653 - 1662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Thomas, M. King, K. Lui, N. Oldridge, I. L. Pina, J. Spertus, R. O. Bonow, N.A. M. Estes III, D. C. Goff, K. L. Grady, et al.
AACVPR/ACC/AHA 2007 Performance Measures on Cardiac Rehabilitation for Referral to and Delivery of Cardiac Rehabilitation/Secondary Prevention Services: Endorsed by the American College of Chest Physicians, American College of Sports Medicine, American Physical Therapy Association, Canadian Association of Cardiac Rehabilitation, European Association for Cardiovascular Prevention and Rehabilitation, Inter-American Heart Foundation, National Association of Clinical Nurse Specialists, Preventive Cardiovascular Nurses Association, and the Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
October 2, 2007;
50(14):
1400 - 1433.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Schaffner, S. J. Rehm, and T. A. Elasy
Influenza Vaccination: An Unmet Need in Patients With Diabetes
Clin. Diabetes,
October 1, 2007;
25(4):
145 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
e1 - e157.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
652 - 726.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E Anderson, K. Brismar, and T. Ivert
Only a minority of patients referred for elective coronary artery bypass surgery have risk factors diagnosed and treated according to established guidelines
Diabetes and Vascular Disease Research,
June 1, 2007;
4(2):
112 - 116.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A. Spinler
Managing acute coronary syndrome: Evidence-based approaches
Am. J. Health Syst. Pharm.,
June 1, 2007;
64(11_Supplement_7):
S14 - S24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sanz, P. R. Moreno, and V. Fuster
The Year in Atherothrombosis
J. Am. Coll. Cardiol.,
April 24, 2007;
49(16):
1740 - 1749.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Guidelines: Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease
Journal Watch Cardiology,
June 8, 2006;
2006(608):
1 - 1.
[Full Text]
|
|
|
|
Top
Appendix
Disclosures